AU2020378207A1 - Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases - Google Patents
Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases Download PDFInfo
- Publication number
- AU2020378207A1 AU2020378207A1 AU2020378207A AU2020378207A AU2020378207A1 AU 2020378207 A1 AU2020378207 A1 AU 2020378207A1 AU 2020378207 A AU2020378207 A AU 2020378207A AU 2020378207 A AU2020378207 A AU 2020378207A AU 2020378207 A1 AU2020378207 A1 AU 2020378207A1
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- fcεriβ
- ms4a6a
- exon
- antisense oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932664P | 2019-11-08 | 2019-11-08 | |
| US62/932,664 | 2019-11-08 | ||
| PCT/US2020/059682 WO2021092562A1 (en) | 2019-11-08 | 2020-11-09 | Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020378207A1 true AU2020378207A1 (en) | 2022-06-23 |
Family
ID=75849333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020378207A Pending AU2020378207A1 (en) | 2019-11-08 | 2020-11-09 | Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12637677B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4054639A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023501347A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115335078A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020378207A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021092562A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
| JP2025531483A (ja) * | 2022-09-28 | 2025-09-19 | アタランタ セラピューティクス,インコーポレーテッド | 神経炎症疾患の治療のための組成物及び方法 |
| CN116219009B (zh) * | 2022-10-19 | 2024-10-01 | 杭州师范大学 | 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989849A (en) | 1991-05-09 | 1999-11-23 | Temple University Of The Commonwealth System Of Higher Education | Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| US20040137566A1 (en) * | 2001-12-10 | 2004-07-15 | Tedder Thomas F. | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| AU2005214287A1 (en) | 2004-02-20 | 2005-09-01 | Genesis Research And Development Corporation Limited | Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders |
| WO2005085443A2 (en) | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| EP2290088A1 (en) | 2004-12-22 | 2011-03-02 | Genentech, Inc. | Methods for producing soluble multi-menbrane-spanning proteins |
| WO2007028065A2 (en) | 2005-08-30 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| WO2009008727A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| ES2566553T3 (es) | 2010-03-17 | 2016-04-13 | Association Institut De Myologie | ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares |
| EP3023496B1 (en) | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US20140080896A1 (en) | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
| DK2581448T3 (en) | 2011-10-13 | 2015-04-27 | Ass Inst De Myologie | Tricyclo-DNA phosphorothioate |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CN103074422A (zh) * | 2012-12-29 | 2013-05-01 | 深圳市第三人民医院 | Ms4a6a基因的用途 |
| US9862945B2 (en) | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| EP3174981B1 (en) | 2014-07-31 | 2020-03-25 | Association Institut de Myologie | Treatment of amyotrophic lateral sclerosis |
| EP2985343A1 (en) | 2014-08-11 | 2016-02-17 | Karlsruher Institut für Technologie | In vitro-co-culturesystem |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| CN105969901B (zh) * | 2016-07-27 | 2019-10-11 | 北京泱深生物信息技术有限公司 | Ms4a6a作为多发性骨髓瘤诊治标志物的用途 |
| WO2019200383A1 (en) * | 2018-04-13 | 2019-10-17 | Ohio State Innovation Foundation | Reagents and methods for autism and comorbidities thereof |
| EP3844278A4 (en) | 2018-08-27 | 2022-05-25 | North Carolina State University | TARGETING KIT WITH SPLICE-SWITCHING OLIGONUCLEOTIDES FOR INDUCING APOPTOSIS OF MASTS CELLS |
-
2020
- 2020-11-09 EP EP20885567.6A patent/EP4054639A4/en active Pending
- 2020-11-09 JP JP2022526035A patent/JP2023501347A/ja active Pending
- 2020-11-09 WO PCT/US2020/059682 patent/WO2021092562A1/en not_active Ceased
- 2020-11-09 AU AU2020378207A patent/AU2020378207A1/en active Pending
- 2020-11-09 US US17/775,136 patent/US12637677B2/en active Active
- 2020-11-09 CN CN202080092446.5A patent/CN115335078A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115335078A (zh) | 2022-11-11 |
| WO2021092562A1 (en) | 2021-05-14 |
| EP4054639A1 (en) | 2022-09-14 |
| JP2023501347A (ja) | 2023-01-18 |
| US20220380777A1 (en) | 2022-12-01 |
| US12637677B2 (en) | 2026-05-26 |
| EP4054639A4 (en) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11596609B2 (en) | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | |
| US20230346928A1 (en) | Mrna combination therapy for the treatment of cancer | |
| US20220380777A1 (en) | Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases | |
| KR102825946B1 (ko) | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 | |
| CN101557831A (zh) | 体内抑制在灵长类亨廷顿基因表达的方法和序列 | |
| US20190241658A1 (en) | Therapeutic mRNAs encoding anti CTLA-4 antibodies | |
| EP3394093B1 (en) | Methods of using ox40 ligand encoding polynucleotides | |
| US6025193A (en) | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression | |
| KR20210110310A (ko) | 올리고머 핵산 분자 및 그의 이용 | |
| US20210363531A1 (en) | Targeting kit with splice switching oligonucleotides to induce apoptosis of mast cells | |
| US20260139273A1 (en) | Synergistic Nucleic Acid Based Therapeutics and Methods of Use for Treating Genetic Disorders | |
| US20220372492A1 (en) | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof | |
| US20150118744A1 (en) | Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector | |
| WO2022022617A1 (en) | Combinatory treatment of sma with sarna and mrna modulators | |
| US10537591B2 (en) | Method for promoting muscle regeneration | |
| JP2002519439A (ja) | Il−15に標的されたアンチセンスオリゴヌクレオチド | |
| US20250327050A1 (en) | Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use | |
| RU2839162C2 (ru) | Молекула олигомерной нуклеиновой кислоты и ее применение | |
| HK40092520A (en) | Combinatory treatment of sma with sarna and mrna modulators | |
| WO2024051765A1 (zh) | 一种cd59基因沉默的t细胞及其应用 | |
| WO2026096962A1 (en) | Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases | |
| US20240002848A1 (en) | Compositions and methods for suppressing msutz | |
| HK1260714A1 (en) | Methods of using ox40 ligand encoding polynucleotides | |
| HK1260714B (en) | Methods of using ox40 ligand encoding polynucleotides |